Major Reform for Rare Disease Treatments on the Horizon in UK

Strategic Insights -

A new paper published by the Medicines and Healthcare products Regulatory Agency (MHRA) outlines a bold new approach to regulating rare disease therapies in the UK. The proposed reforms aim to speed up the development and approval of life-saving treatments for the estimated 3.5 million people living with a rare disease in the country. The MHRA's plan is to overhaul the current rulebook for rare therapies, making it quicker and easier to get these treatments tested, manufactured, and approved in the UK.

The UK has one of the highest rates of rare disease diagnosis in the world, with only 5% of rare diseases having an approved treatment. The average diagnostic journey for a rare disease takes 5.6 years, and 30% of affected children die before the age of five. The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually, with a further £4.7 billion in health-related disability costs and a £14.9 billion annual loss to the economy.

The MHRA's paper proposes several innovative changes to the regulatory framework, including:

  • Issuing an early, single approval for both a clinical trial application and marketing authorization based on compelling but limited evidence
  • Better sharing of evidence in the UK and globally to pool scarce data
  • Issuing a single approval for a therapy with a variable component tailored to an individual's characteristics
  • Strengthened post-market surveillance
  • Improved health system alignment in the UK and internationally

These reforms aim to tackle the unique barriers that prevent life-changing rare disease therapies from reaching patients, such as small patient numbers and difficult evidence generation. The MHRA is committed to maintaining safety while speeding up the development and approval of these treatments.

Key Takeaways:

  • The MHRA is proposing a major reform of the regulatory framework for rare disease therapies in the UK, aiming to speed up the development and approval of life-saving treatments.
  • The UK has a high rate of rare disease diagnosis, with only 5% of rare diseases having an approved treatment.
  • The average diagnostic journey for a rare disease takes 5.6 years, and 30% of affected children die before the age of five.
  • The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually, with a further £4.7 billion in health-related disability costs and a £14.9 billion annual loss to the economy.
  • The MHRA is proposing to overhaul the current rulebook for rare therapies to make it quicker and easier to get these treatments tested, manufactured, and approved in the UK.
  • The proposed reforms aim to tackle the unique barriers that prevent life-changing rare disease therapies from reaching patients.
  • The MHRA is committed to maintaining safety while speeding up the development and approval of these treatments.

Statistics:

  • 3.5 million people in the UK live with a rare disease, equivalent to one in 17 people.
  • Only 5% of rare diseases have an approved treatment.
  • The average diagnostic journey for a rare disease takes 5.6 years.
  • 30% of affected children die before the age of five.
  • The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually.
  • The further £4.7 billion in health-related disability costs and a £14.9 billion annual loss to the economy.

Sources:

  • "Overhauling the rulebook for rare therapies" by the Medicines and Healthcare products Regulatory Agency (MHRA).
  • "Rare Disease Action Plan" by the Government of the United Kingdom.
  • "Wellcome NHRS" by the Wellcome Trust.
  • "Catapult Cell and Gene Therapy" by the Cell and Gene Therapy Catapult.